Michael Oredsson appointed CEO of Probi

Michael Oredsson appointed CEO of Probi

Michael Oredsson has been appointed Chief Executive Officer of Probi AB. Mr.
Oredsson has been CEO of listed Australian biotech corporation Biosignal since
February 2002, where he headed the company's growth and listing on the Sydney
Stock Exchange.

“Probi has great products with sizeable future opportunities and skilled
employees,” commented Mr. Oredsson, “I look forward to taking up the challenge
of continuing to develop the company and realizing the potential of the
impressive research portfolio.”

Under Mr. Oredsson's leadership, Biosignal, which offers an entirely new
antibacterial technology, successfully signed a series of R&D and licensing
agreements with global medical and industrial corporations. In 1999-2001,
Michael was CEO of the Norwegian biotech company Nutripharma, where he had a key
role in its IPO and build-up into an international corporation. Nutripharma also
signed a number of licensing agreements with global food corporations under his
management.

“I'm delighted that Michael has accepted the offer to be the new CEO of Probi,”
commented Peter Zakrisson, Probi's Chairman, “Michael has extensive experience
of building and developing businesses in the biotech sector. His proven capacity
to lead and build businesses, plus his experience of international sales and
marketing, makes him very well suited to take Probi to the next level of its
development.”

Michael's previous responsibilities included building Pharmacia's Australian OTC
products division from scratch, plus a series of senior marketing executive
positions for Nestlé and Mars Inc. in Sweden, Germany and France.

Rolf Bjerndell will remain Probi's acting CEO until Mr. Oredsson takes up his
position, which is scheduled for the early autumn. Per-Ola Forsberg will
continue as Executive Vice President in the company.

For further information, please contact:
Peter Zakrisson, Chairman of the Board, ph: +46-8-545 680 61 or mobile
+46-709-50 96 20
Michael Oredsson, ph: +61414385064 or email m.oredsson@biosignal.com.au


About Probi 
Probi was founded in 1991 and is now one of the world's leading companies in the
field of probiotic R&D. The company's research focuses on live micro-organisms
with scientifically demonstrated health-promoting effects. The main R&D fields
are gastrointestinal disorders, the immune system, cardiovascular diseases, and
stress and performance recovery. Probi's business is based on offering effective
and thoroughly documented probiotic products and concepts, protected by
comprehensive patents. This yields higher revenue levels than for the industry
as a whole. Probi has enjoyed a consistent income stream from commercialised
products since the mid-1990s. The customers comprise leading international
companies in the fields of functional food, dietary supplements and clinical
nutrition. The global market for probiotic products is showing good underlying
growth while new insights into the benefits offered by probiotics are boosting
the market still further. Increased documentation requirements and official
regulation are two trends that tend to give Probi an edge on its competitors.
Probi is based in Lund and has 17 employees. The Probi share is quoted on the
Nordic Stock Exchange. Fore more information, please visit www.probi.com